Breast cancer: Pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics

Annals of Oncology

Volumn 8, Issue 4, 1997, Pages 335-341

  Buser, K ^a,e   Joncourt, F ^b   Altermatt, H J ^c   Bacchi, M ^d   Oberli, A ^b   Cerny, Th ^a  

^a Department of Plastic   (Switzerland)

^b Inst of Clin and Exp Cancer Res   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d SIAK Coordinating Center   (Switzerland)

^e Klinik Beau Site   (Switzerland)

Author keywords

ATase; Breast cancer; Drug resistance; GPx; GSH; GST; PGP; Prognosis

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030907575     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008202723066     Document Type: Article

References (33)

1. Boring CC, Squires TS, Tung T. Cancer statistics 1988. CA 1991: 1: 19-36.
2. Elledge RM, MC Guire WL, Osborne CK. Prognostic factors in breast cancer. Semin Oncol 1992; 19: 244-53.
3. Mross K, Bohn C, Edler L et al. Randomized phase II study of single agent epirubicin +/-verapamil in patients with advanced breast cancer. Ann Oncol 1993; 4: 45-50.
4. D'lncalci M, Broxterman HJ, Van Kalken CK. Membrane transport multidrug resistance, development and disease. Ann Oncol 1991; 2: 635-9.
5. Botti G, Chiappelta G, D'Aiuto G et al. PCNA Cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical. retrospective study. Tumori 1993; 79: 214-8.
6. Gottesman NM. How cancer cells evade chemotherapy: Sixteenth Richard and Minda Rosenthal Foundation Award lecture. Cancer Res 1993; 53: 747-54.
7. Murray GI, Burke MD, Ewen SWB. Glutathione localization in benign and malignant human breast lesions. Br J Cancer 1987; 55: 605-9.
8. 6-alkyl-guanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 1991; 51: 2092-7.
9. 6-alkyl-guanine-DNA alkyltransferase and P-glycoprotein as indicators ofdrug resistance in tumor and normal lung of patients with lung cancer. Int J Cancer 1994; 59: 629-36.
10. Colovai AI, Stoica A, Cinca SA et al. Glutathione S-transferase activity in human breast cancer tumors. Neoplasma 1992; 39: 249-54.
11. Gilbert L, Elwood LJ, Merino M et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: Correlation with estrogen receptor expression and prognosis. J Clin Oncol 1993; 1: 49-58.
12. Singh SV, Brunnert SR, Roberts B, Krishan A. Differential expression of glulathione S-transferase. glutathione peroxidase and glutathione reductase in normal and malignant human breast tissue. Cancer Lett 1990; 51: 43-8.
13. 6-alkylguanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1988; 15: 279-92.
14. 6-methylguanine-DNA methyltransferase activity and its application to human neoplastic and nonneoplastic tissues. Carcinogenesis 1984; 5: 1061-4.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
16. Korenmann SG, Dukes BA. Specific estrogen binding by the cytoplasm of human breast carcinoma. J Clin Endocrinol Metabol 1970; 30: 639-45.
17. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4: 87-90.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 457-81.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-7.
20. Joncourt F, Oberli AE, Studler M et al. Patterns of drug resistance parameters in adult leukemia. Leuk Lymph 1995; 17: 101-9.
21. Wishart GC, Plump JA, Going JJ et al. P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-61.
22. Wallner J, Depisch D, Hopfner M et al. MDRI gene expression and prognostic factors in primary breast cancer. Eur J Cancer 1991; 27: 1352-5.
23. Linn SC, Giaccone G, Van Diest PJ et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 1995; 6: 679-85.
24. Decker DA, Morris LW, Levine AJ et al. Immunohistochemical analysis of P-glycoprotein expression in breast cancer: Clinical correlations. Ann Clin Lab Sci 1995; 25: 52-9.
25. 6-alkylguanine-DNA-alkyltransferase and P-glycoprotein in adult patients with leukemia. Br J Haematol 1993; 85: 103-11.
26. Verelle P, Meissonnier F, Fonck Y et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Nail Cancer Inst 1991; 83: 111-6.
27. Perry RR, Mazetta JA, Levin M, Barranco SC, Glutathione levels and variability in breast tumors and normal tissue. Cancer 1993; 72: 783-7.
28. Cairns J, Wright C, Cattan AR et al. Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas. J Pathol 1992; 166: 19-15.
29. Efferth T, Volm M. Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquiredor inherent multidrug-resistance. Cancer Detect Prev 1992; 16: 237-43.
30. Lohri A, Van Hille B, Bacchi M et al. Simultaneous assessment of five putative drug resistance (DR) parameters (MDR1/P-glycoprotein [PGP]. MDR-associated protein [MRP], Glutathione-S-Transferase [GST]. bcl-2 and topoisomerase lia [Topo lia]) in 57 newly diagnosed acute myeloid leukemia's (AML). ASCO Proc 1995; 14: 179.
31. Ohwada M, Suzuki M, Sato I et al. Glutathione peroxidase activity in endometrium: Effects of sex hormones and cancer. Gynecol Oncol 1996; 60: 277-82.
32. 6-alkylguanine-DNA alkyltranslerase expression in rat mammary epithelial cells. Cancer Lett 1993; 75: 11-8.
33. Linn SC, Van Kalken CK, Van Tellingen O et al. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 1994; 12: 812-9.